GT
PRAX icon

Glenmede Trust’s Praxis Precision Medicines PRAX Stock Holding History

Glenmede Trust’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.37M Buy
4,096
+686
+20% +$217K 0.01% 683
2026
Q1 		$1.1M Sell
3,410
-2,878
-46% -$890K 0.01% 711
2025
Q4 		$1.85M Buy
+6,288
New +$1.17M 0.01% 580
2025
Q1 		– Sell
-3,809
Closed -$293K – 1427
2024
Q4 		$293K Sell
3,809
-364
-9% -$26.3K ﹤0.01% 1107
2024
Q3 		$240K Buy
+4,173
New +$225K ﹤0.01% 1173

Other funds holding PRAX

JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Glenmede Trust's PRAX Position: Q2 2026 in Review

Glenmede Trust increased its Praxis Precision Medicines (PRAX) stake by 20% in Q2 2026, buying an estimated $217K and bringing the position to 4,096 shares worth $1.37M. The position accounts for 0.01% of the portfolio, ranked #683.

Glenmede Trust first reported a position in PRAX in Q3 2024 and has held it in 5 quarters since. The position peaked at $1.85M in Q4 2025. 309 funds tracked by Wall St. Rank hold PRAX as of Q2 2026.

  • Glenmede Trust held 4,096 shares of Praxis Precision Medicines worth $1.37M as of Q2 2026.
  • Glenmede Trust bought 686 Praxis Precision Medicines shares in Q2 2026, an estimated $217K.
  • Praxis Precision Medicines made up 0.01% of Glenmede Trust's portfolio in Q2 2026, its #683 holding.
  • Glenmede Trust first reported a position in Praxis Precision Medicines in Q3 2024 and has held it in 5 quarters since.
  • Glenmede Trust's Praxis Precision Medicines position peaked at $1.85M in Q4 2025.
  • 309 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2026.

Based on Glenmede Trust's 13F filing for Q2 2026, filed 10 Aug 2026.